Is bipolar sealer superior than standard electrocautery for blood loss control after primary total knee arthroplasty

A meta-analysis

Xinxin Chen, MM, Wenhui Yang, MM, Xiao Wang, MM∗

Abstract

Background: Whether bipolar sealer (BS) is superior to standard electrocautery in patients with primary total knee arthroplasty (TKA) remains controversial. Thus, we conducted this meta-analysis involving comparative studies (S) to evaluate whether administration with BS (I) was associated with less blood loss (O) than standard electrocautery (C) after primary TKA (P).

Methods: PubMed (1950–January 2017), EMBASE (1974–January 2017), the Cochrane Library (January 2017 Issue 3), and the Google database (1950–January 2017) were systematically searched. Studies were included in accordance with Population, Intervention, Comparison, Outcomes, and Setting including criteria. Only the patients prepared for primary TKA and administered with BS as the intervention group and standard electrocautery as control group were included in this meta-analysis. Outcomes include need for transfusion, total blood loss, blood loss in drainage, hemoglobin at discharge, hemoglobin drop, and length of hospital stay. Continuous outcomes and discontinuous outcomes were expressed as weighted mean difference (WMD) and risk ratio (RR) with corresponding confidence intervals (CIs), respectively. Stata 13.0 software was used for relevant data calculation.

Results: A total of 7 clinical trials with 718 patients (398 patients in BS group and 320 in standard electrocautery group) were finally included in this meta-analysis. The pooled results indicated that administration with BS was associated with little reduction of total blood loss (WMD = −123.80, 95%CI −236.56 to −11.04, P = .031). There was no significant difference between the need for transfusion, blood loss in drainage, hemoglobin at discharge, hemoglobin drop, and length of hospital stay (P > .05).

Conclusion: Based on the current meta-analysis, we found no evidence to support the routine use of bipolar sealer in the management of blood loss in primary TKA. Since the poor quality of the included studies, more randomized controlled trials are still needed to further identify the efficacy of BS after primary TKA.

Abbreviations: CENTRAL = Cochrane Controlled Trials Register, MD = mean difference, Mesh = medical subject heading, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RCTs = randomized controlled trials, RR = risk ratio, TKA = total knee arthroplasty, TXA = tranexamic acid.

Keywords: bipolar sealer, blood loss, meta-analysis, total knee arthroplasty

1. Introduction

Primary total knee arthroplasty (TKA) is associated with extensive blood loss and a need for intraoperative and postoperative blood transfusion.[1,2] Blood transfusion is associated with ethical, technical, and financial shortcomings.[3,4] Intraoperative blood loss accounts a large portion of total blood loss in primary TKA.[1,4] Standard electrocautery has been used widespread to keep bleeding away from the operative field by blood vessel cauterization; however, administration with standard electrocautery has been accompanied by severe patient burns, operating room fires and even tissue necrosis.[5–9] Bipolar sealers (BSs) combined bipolar radiofrequency energy with continuous saline flow to prevent charring or burning tissue or produce smoke[2,10] and the temperature at tissue is 100°C or less. There have been several randomized controlled trials (RCTs) published; however, there is no consensus about the efficacy of BS in reducing blood loss and need for transfusion after primary TKA. Thus, we perform this meta-analysis to further identify the efficacy of BS after primary TKA. The purpose of this
The electronic databases PubMed (1950–January 2017), EMBASE (1974–January 2017), the Cochrane Library (January 2017 Issue 3), and the Google database (1950–January 2017) were systematically searched by two reviewers (ZYS and ZHL). The detailed PubMed search strategy can be seen in Supplement S1, http://links.lww.com/MD/D354. In addition, the reference lists of all the full-text literatures and relevant meta-analysis were reviewed to identify any initially omitted studies. There was no restriction on the language of the publication. Meta-analysis was collected from published data and thus ethical review or approval was not necessary. The reliability of the study selection was determined by Cohen’s kappa test, and the acceptable threshold value was set at 0.61. All domains were evaluated as “low”, “high”, or “unclear”. Kappa values were used to measure the degree of agreement between the 2 reviewers and were rated as follows: fair, 0.40 to 0.59; good, 0.60 to 0.74; and excellent, 0.75 or more.}

2. Materials and methods

The method of this study was designed and reported according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Cochrane Handbook for Systematic Reviews of Interventions. It was prospectively registered in the Researchregistry (reviewregistry674). Methods of this meta-analysis were based on Population, Intervention, Comparison, Outcomes, and Setting guidelines.

2.1. Search strategies

The following criteria were predefined for inclusion:

1. Participants (P): Patients undergoing primary TKA.
2. Interventions (I): The comparison group was an administration of BS.
3. Comparisons (C): The comparison group was with standard electrocautery.
4. Outcomes (O): Need for transfusion, total blood loss, blood loss in drainage, hemoglobin at discharge, and length of hospital stay.
5. Study design (S): RCTs and non-RCTs were included.

Studies were excluded if they:

1. Overlapping with other studies or overlapping with data from the same authors,
2. Letter or meeting abstracts,
3. Had no control group or intervention groups (bipolar sealer),
4. Did not report results adequately.

2.2. Inclusion criteria and exclusion criteria

2.3. Study quality

The following criteria were predefined for inclusion:

1. Overlapping with other studies or overlapping with data from the same authors,
2. Letter or meeting abstracts,
3. Had no control group or intervention groups (bipolar sealer),
4. Did not report results adequately.

2.4. Data extraction

2.5. Quality of evidence assessment

2.6. Outcome measures and statistical analysis

The main outcomes were need for transfusion, total blood loss, blood loss in drainage, hemoglobin at discharge, and hemoglobin drop, and length of hospital stay. Continuous outcomes (total blood loss, blood loss in drainage, hemoglobin at discharge, and hemoglobin drop) were expressed as the mean differences (MDs) and respective 95% confidence intervals (CIs). Dichotomous outcomes (need for transfusion) were expressed as relative risks (RRs) with 95% CIs. Statistical significance was set at $P < .05$ to summarize findings across the trials. Risk of bias assessment of each involved RCTs was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions. Non-RCTs were assessed by Newcastle-Ottawa Scale (NOS). The meta-analysis was performed using Stata software, version 12.0 (Stata Corp., College Station, TX). Statistical heterogeneity was tested using the chi-squared test and $I^2$ statistic. Random model was used to perform the meta-analysis. If the heterogeneity is large, a sensitivity analysis and subgroup analysis were conducted to further seek out the source of heterogeneity. Publication bias was assessed by funnel plot and quantitatively assessed by Begg’s test. Publications were considered to have no publication bias if the funnel plot was symmetrical and the $P$ value was $>.05$.

3. Results

3.1. Search results

The literature search and selection process are illustrated in Figure 1. The initial search yielded 361 papers (PubMed=112,
Embase = 92, Web of Science = 50, Cochrane Library = 50, Google database = 57]; 273 papers were read after excluding the duplicates by Endnote Software (Version X7, Thompson Reuters, USA). Next, 264 papers were excluded based on the inclusion criteria. 2 papers were then excluded as the participants were revision TKAs.[17,18] Of these, we included 7 clinical trials with 718 patients (398 patients in BS group and 320 in standard electrocautery group) in the meta-analysis.[2,19–26] The sample size from each study ranged from 20 to 203 and the mean age ranged from 55.9 to 72.2. The general characteristic of the included studies is shown in Table 1 and Supplement S2, http://links.lww.com/MD/D354. There was no significant difference between the preoperative hematology screening such as anemia and coagulopathy.

3.2. Quality assessment

The quality assessment of included RCTs is shown in Figures 2 and 3. Two studies reported the random sequence generation and allocation concealment,[20,24] one study[23] did not report the method of random sequence generation and allocation concealment and thus was classified as “unclear bias”. Surgeons performed TKAs and it was not blinded to the personnel.[20,23,24] The quality of blinding to outcome assessment, incomplete
outcome data, selective reporting, and other bias were all with low bias. The quality of non-RCTs is shown in Table 2. The total score of Diedo et al,[19] Pfeiffer et al,[22] Kamath et al,[25] and Rosenthal et al[26] was 18, 24, 17, and 23, respectively.

### 3.3. Quality of evidence assessment

A summary of the quality of the evidence based on the GRADE approach is shown in Supplement S3, http://links.lww.com/MD/D354. The GRADE level of evidence was moderate for need for transfusion, low for total blood loss and hemoglobin at discharge, very low for blood loss in drainage, hemoglobin drop and length of hospital stay.

### Table 1

The general characteristic of the included studies.

| Author and yr | Country | Case (BP/C) | Mean age (BP/C) | Male patients (BP/C) | Intervention | Control | Study type | Prosthesis | TXA use | Outcomes | Prophylactic antithrombotic | Follow-up |
|---------------|---------|-------------|----------------|----------------------|--------------|---------|-----------|------------|---------|----------|---------------------------|-----------|
| Diedo 2013    | USA     | 30/90       | 65.7/67.3      | NS                   | Bipolar sealer| Standard electrocautery | RCS       | NS        | NS       | 1         | NS                   | 3 d       |
| Marulanda 2009| USA     | 35/34       | 66/66          | 22/23                | Bipolar sealer| Standard electrocautery | RCTs      | NS        | NS       | 1, 2, 3   | 5, 6, 7       | 3 mo      |
| Pfeiffer 2005 | Germany | 20/20       | 72/NS          | 13/NS                | Bipolar sealer| Standard electrocautery | PCS       | Cemented  | NS       | 2, 3, 4   | NS                   |           |
| Plymale 2012  | USA     | 50/61       | 38/51          | 64.9/66.3            | Bipolar sealer| Standard electrocautery | RCTs      | Cemented  | NS       | 1, 3, 4, 5| LMWH             | 2 d       |
| Seviciu 2016  | USA     | 31/32       | 64.8/62.9      | 14/14                | Bipolar sealer| Standard electrocautery | RCTs      | Cemented  | NS       | 2, 5, 7   | NS                   | 3 d       |
| Kamath 2014   | USA     | 29/42       | 59.1/63.4      | 15/28                | Bipolar sealer| Standard electrocautery | CCS       | NS        | NS       | 1, 2, 3, 4| 5, 6, 7       |           |
| Rosenthal 2016| USA     | 203/41      | 65/61.5        | NS                   | Bipolar sealer| Standard electrocautery | RCS       | Cemented  | NS       | 1, 2, 3, 4| 4, 5, 7       |           |

BP/C = bipolar sealer/control, CCS = case controlled study, LMWH = low molecular weight heparin, NS = not stated, PCS = prospective controlled study, RCS = retrospective comparable study, RCTs = randomized controlled trials, TXA = tranexamic acid, 1 = need for transfusion, 2 = total blood loss, 3 = blood loss in drainage, 4 = hemoglobin at discharge, 5 = hemoglobin drop, 6 = transfusion unit per patient, 7 = length of hospital stay.

### Table 2

The minors quality score of the non-RCTs; “0” represent high risk of bias; “1” represent unclear risk of bias; “2” represent low risk of bias.

| Items                                      | Diedo 2013 | Pfeiffer 2005 | Kamath 2014 | Rosenthal 2016 |
|--------------------------------------------|------------|---------------|-------------|----------------|
| A clearly stated aim                       | 2          | 2             | 2           | 2              |
| Inclusion of consecutive patients          | 1          | 2             | 2           | 2              |
| Prospective collection of data             | 1          | 2             | 0           | 1              |
| Endpoints appropriate to the aim of the study | 2          | 2             | 2           | 2              |
| Unbiased assessment of the study endpoint  | 0          | 2             | 0           | 2              |
| Follow-up period appropriate to the aim of the study | 2          | 2             | 2           | 2              |
| Loss to follow-up less than 5%             | 2          | 2             | 2           | 2              |
| Prospective calculation of the study size  | 0          | 2             | 0           | 2              |
| An adequate control group                  | 2          | 2             | 2           | 2              |
| Contemporary groups                        | 2          | 2             | 1           | 2              |
| Baseline equivalence of groups             | 2          | 2             | 2           | 2              |
| Adequate statistical analyses              | 2          | 2             | 2           | 2              |
| Total scores                               | 18         | 24            | 17          | 23             |

4. Results of meta-analysis

4.1. Need for transfusion

A total of five trials tested the need for transfusion after TKA, and pooled meta-analysis indicated that there is no significant difference between the BS and standard electrocautery in terms...
of the need for transfusion (RR=0.86, 95%CI 0.61–1.21, \( P = .337 \), Fig. 4) with low heterogeneity (\( I^2 = 38.4\% \), \( P = .165 \)).

A funnel plot was drawn and shows that there is no bias between the included studies indicating a need for transfusion (Fig. 5A); moreover, the \( P \) value obtained from the Begg’s test is 0.806 and this also indicated that there is no bias (Fig. 5B).

### 4.2. Total blood loss

A total of five trials reported the total blood loss after TKA and pooled results indicating that the BS can decrease the total blood loss in a statistically significant manner with a mean of 123.80 ml (weighted mean difference (WMD) = −123.80, 95%CI −236.56 to −11.04, \( P = .031 \), Fig. 6) with high heterogeneity (\( I^2 = 74.3\% \), \( P = .004 \)).
The results of sensitivity analysis show that no studies affected the heterogeneity of the total blood loss, and the detail of this information is shown in Figure 7.

4.3. Blood loss in drainage

Four trials were performed about the blood loss in drainage after primary TKA, and pooled meta-analysis indicated that there is no significant difference between the bipolar and standard electrocautery in terms of blood loss in drainage after primary TKA (WMD = −47.29, 95% CI −271.14 to 176.56, P = .679, Fig. 8) with high heterogeneity (I² = 89.9%, P = .003).

4.4. Hemoglobin at discharge

Three studies were available for the data of hemoglobin at discharge. Results indicated that there was no significant difference between the hemoglobin at discharge (WMD = 0.23, 95% CI −0.29 to 0.75, P = .380, Fig. 9) with high heterogeneity (I² = 78.1%, P = .003).

4.5. Hemoglobin drop

A total of five trials with 394 patients reported the hemoglobin drop after primary TKA, and pooled meta-analysis indicated that there is no significant difference between the BS and standard electrocautery in terms of hemoglobin drop (WMD = 0.11, 95% CI −0.38 to 0.59, P = .668, Fig. 10) with high heterogeneity (I² = 78.7%, P = .001).

4.6. Length of hospital stay

Three trials with 203 patients reported the length of the hospital stay after the use of the BS and standard electrocautery. Results
Figure 6. Forest plots comparing total blood loss between BS and standard electrocautery from the included studies.

Figure 7. Sensitivity analysis of the total blood loss.
Figure 8. Forest plots comparing blood loss in drainage between BS and standard electrocautery from the included studies.

Figure 9. Forest plots comparing hemoglobin at discharge between BS and standard electrocautery from the included studies.
indicated that there was no significant difference between the length of hospital stay (WMD = −0.08, 95% CI −0.23 to 0.13, \(P = 0.590\), Fig. 11) with no heterogeneity (\(I^2 = 0.0\%, P = 0.779\)).

### 4.7. Subgroup analysis

All the variables show a large heterogeneity between the included studies, and thus a subgroup analysis was conducted to further analyze the results. Since RCTs and non-RCTs were both included in this meta-analysis, subgroup analysis was based on the research type of the included studies. The final results are shown in Table 3.

### 5. Discussion

To our knowledge, no previous study has assessed the effectiveness and safety based on the BS and standard electrocautery following primary TKA. Final results indicated that BS can decrease the total blood loss by 123.80 ml in a statistically significant manner. However, no statistical significance was found between the hemoglobin drop, need for transfusion, and hospital stay. The GRADE level of evidence was moderate for need for transfusion, low for total blood loss and hemoglobin at discharge, very low for blood loss in drainage, hemoglobin drop and length of hospital stay.

Yang et al\(^{[27]}\) revealed that administration with BS was associated with a small, but not clinically important, reduction in intraoperative blood than standard electrocautery in primary THA. The pooled results indicated that BS can decrease the total blood loss in a statistically significant manner with a mean of 123.80 ml. A total blood loss with 123.80 ml seems not clinically important. Min et al\(^{[28]}\) conducted an updated meta-analysis and revealed that BS was associated with a reduction of total blood loss by 226.57 ml in primary THA. Li et al\(^{[29]}\) revealed that BS was associated with a reduction of total blood loss by 165.23 ml. However, primary TKAs and revision TKAs were all included in that study. Because of the large heterogeneity, subgroup was then performed and results indicated that BS was associated with a reduction of total blood loss by 131.95 ml in the RCTs.

Perioperative blood loss during TKA is reported at about 800 ml to 1800 ml, and postoperative anemia has an adverse effect on morbidity and mortality of affected patients.\(^{[30–35]}\) There were no significant differences between hemoglobin at discharge, hemoglobin drop, need for transfusion, blood loss in drainage, and length of hospital stay (\(P > 0.05\)). The subgroup analyses results indicated that there was still heterogeneity between the studies in terms of hemoglobin drop and the need for transfusion. Fukui et al\(^{[36]}\) revealed that BS was effective in shortening the length of hospital stay in lumbar posterolateral fusion. Marulanda et al\(^{[2,20]}\) published two relevant studies about the hemostasis effects of BS in reducing intraoperative blood loss in primary TKA. Final results indicated that BS may be of limited benefit except in intraoperative blood loss.

Meanwhile, complications associated with BS have also emerged, including the concern of early postoperative periprosthetic femoral condyle fracture after extensive administration in...
The occurrence of complications was attempted to be compiled to assess the safety of BS; however, there was insufficient data to support the safety of BS in primary TKA. One study revealed that BS can decrease the occurrence of infection in revision TKAs and this affects the need for more studies to further identify.

A major strength of current meta-analysis was the patients’ selection and rigorous statistical calculation. PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and Google scholar were systematically retrieved and no language was restrained. Finally, a total of seven trials fulfilled the inclusive criteria and thus were included in this meta-analysis.

The overall methodological quality of the included 3 RCTs was relatively high. Only one study did not state the randomized sequential generation and did not reveal the allocation concealment and blinding. Another two trials give detailed information on the randomized sequential generation, allocation concealment,

| Variables                      | Studies (n) | Patients (n) | P-value | 95%CI       | Heterogeneity | P-value (I²) | Model   |
|--------------------------------|-------------|--------------|---------|-------------|---------------|--------------|---------|
| Hemoglobin drop                | 3           | 244          | .812    | -0.414, 0.315 | 72.1          | Random      |
| Total blood loss               | 2           | 132          | .036    | -150.05, -26.52 | 0             | Fixed       |
| Blood loss in drainage         | 2           | 180          | .464    | -129.53, 59.04 | 0             | Fixed       |
| Length of hospital stay        | 2           | 132          | .513    | -0.287, 0.206  | 0             | Random      |
| Need for transfusion           | 2           | 180          | .503    | 0.474, 1.531   | 55            | Random      |
| Hemoglobin at discharge        | 2           | 215          | .255    | -0.33, 0.61    | 61            | Random      |

CI = confidence interval, RCTs = randomized controlled trials.
and blinding. Though 4 non-RCTs were included in our meta-analysis, the baseline of the included non-RCTs was relative with one accord and relatively high quality.

There were several limitations in this meta-analysis:

1. only 3 RCTs and 4 non-RCTs were included, the relative small number of the eligible studies will affect the final results;
2. the duration of follow-up in some studies was unclear, and long-term follow-up was needed for testing the function outcomes of hips;
3. the publication bias that existed in the meta-analysis influenced the results;
4. the concomitant use of TXA may have confounded the data in any of the studies as this likely has a significant effect on blood loss reduction during primary TKA;
5. the included studies did report on tourniquet time, and longer tourniquet time would expect a reduction in intraoperative blood loss for that series and possibly a reduced transfusion rate for primary TKA and may cause heterogeneity between the studies;
6. the heterogeneity among the studies will also affect the final conclusion, although we tried to use subgroup analysis to solve it.

6. Conclusion
BS has limited hemostasis effects after primary TKA. What’s more, there was no significant difference between the two groups in terms of the length of hospital stay. Due to the included number and the quality of the studies, there is still a need for high-quality RCTs to further identify the effect of BS on the blood loss in TKA.

We did not recommend BS as a routine hemostasis method in primary TKA patients. Future studies should be focused on the knee functional outcomes and the potential complications during surgery.

Author contributions
Data curation: Xinxin Chen, Xiao Wang.
Visualization: Wenhui Yang.
Writing – original draft: Wenhui Yang.
Writing – review and editing: Xinxin Chen, Xiao Wang.

References
1. Cushner FD, Scott WN. Evolution of blood transfusion management for a busy knee practice. Orthopedics 1999;22(Suppl):s145–7.
2. Marulanda GA, Ragland PS, Seyler TM, et al. Reductions in blood loss with use of a bipolar sealer for hemostasis in primary total knee arthroplasty. Surg Technol Int 2005;14:281–6.
3. Dramis A, Plewes J. Autologous blood transfusion after primary unilateral total knee replacement surgery. Acta Orthop Belg 2006; 72:15–7.
4. Woolston ST, Wall WW. Autologous blood transfusion after total knee arthroplasty: a randomized, prospective study comparing predonated and postoperative salvage blood. J Arthroplasty 2003;18:243–9.
5. Nielsen CS, Jans O, Orsnes T, et al. Combined intra-articular and intravenous tranexamic acid reduces blood loss in total knee arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am 2016;98:835–42.
6. Fillingham YA, Kayupov E, Plummer DR, et al. A randomized controlled trial of oral and intravenous tranexamic acid in total knee arthroplasty: the same efficacy at lower cost? J Arthroplasty 2016;31(Suppl):26–30.
7. Wang X, Sun G, Sun R, et al. Bipolar sealer device reduces blood loss and transfusion requirements in posterior spinal fusion for degenerative lumbar scoliosis: a randomized control trial. Clin Spine Surg 2016;29: E107–11.
8. Hollmann R, Hert CE, Kammer E, et al. Smoke in the operating theater: an unregarded source of danger. Plast Reconstr Surg 2004;114:458–63.
9. Nercessian OA, Wu H, Nazarian D, et al. Intraoperative pacemaker dysfunction caused by the use of electrocautery during a total hip arthroplasty. J Arthroplasty 1998;13:599–402.
10. Rosenberg AG. Reducing blood loss in total joint surgery with a saline-coupled bipolar sealing technology. J Arthroplasty 2007;22(Suppl 1):82–5.
11. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
12. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
13. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. 2011, http://www.cochrane-handbook.org.
14. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–6.
15. Guyatt GH, Oxman AD, Kunz R, et al. What is “quality of evidence” and why is it important to clinicians? BMJ 2008;336:995–8.
16. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
17. Derman PB, Kamath AF, Lee GC. Saline-coupled bipolar sealing in revision total knee arthroplasty for infection. Am J Orthop (Belle Mead NJ) 2013;42:407–11.
18. Nielsen CS, Gromov K, Jans O, et al. No effect of a bipolar sealer on total blood loss or blood transfusion in nonseptic revision knee arthroplasty – a prospective study with matched retrospective controls. J Arthroplasty 2017;32:177–82.
19. Diedo N, Moore G, Otten C. Effectiveness of the bipolar sealer in reducing blood loss in total knee arthroplasty. Int J Orthop Trauma Nurs 2013;17:29–37.
20. Marulanda GA, Krebs VE, Bierbaum BE, et al. Hemostasis using a bipolar sealer in primary unilateral total knee arthroplasty. Am J Orthop (Belle Mead NJ) 2009;38:E179–83.
21. Pleifre M, Brautigam H, Sigg A. Use of a new bipolar sealing system to reduce blood loss during total knee arthroplasty: results of a prospective matched-pair study. Ger Med Sci 2014;3:12–8.
22. Pleifre M, Brautigam H, Drawes D, et al. A new bipolar sealing system embedded in peroperative strategies vs. a conventional regimen for total knee arthroplasty: results of a matched-pair study. Ger Med Sci 2005;3; Doc10.
23. Pymalic MF, Capogna BM, Love AJ, et al. Unipolar vs bipolar hemostasis in total knee arthroplasty: a prospective randomized trial. J Arthroplasty 2012;27:1133–7.
24. Seviciu A, Gross I, Fathima S, et al. Effects of tranexamic acid and bipolar sealer alone or in combination in primary total knee arthroplasty: a prospective, randomized, controlled trial. Arthroplasty Today 2016; 2:77–82.
25. Kamath AF, Austin DC, Derman PB, et al. Saline-coupled bipolar sealing in simultaneous bilateral total knee arthroplasty. Clin Orthop Surg 2014;6:298–304.
26. Rosenthal BD, Haughom BD, Levine BR. A retrospective analysis of hemostatic techniques in primary total knee arthroplasty: traditional electrocautery, bipolar sealer, and argon beam coagulation. Am J Orthop (Belle Mead NJ) 2016;45:E187–91.
27. Yang Y, Zhang LC, Xu F, et al. Bipolar sealer not superior to standard electrocautery in primary total hip arthroplasty: a meta-analysis. J Orthop Surg Res 2014;9:92.
28. Min JK, Zhang QH, Li HD, et al. The efficacy of bipolar sealer on blood loss in primary total hip arthroplasty: a meta-analysis. Medicine (Baltimore) 2016;95:e5435.
29. Li H-Z, Li X-Q, Zhao G-Z, et al. The efficacy of bipolar sealer for blood loss control after total knee arthroplasty: a meta-analysis. Int J Clin Exp Med 2017;10:1778–87.
30. Kalairajah Y, Simpson D, Cossey AJ, et al. Blood loss after total knee replacement: effects of computer-assisted surgery. J Bone Joint Surg Br 2005;87:1480–2.
31. Banerjee S, Issa K, Pivec R, et al. Intraoperative pharmacotherapeutic blood management strategies in total knee arthroplasty. J Knee Surg 2013;26:379–85.
[32] Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account. Knee 2000;7:151–5.

[33] Maniar RN, Kumar G, Singhi T, et al. Most effective regimen of tranexamic acid in knee arthroplasty: a prospective randomized controlled study in 240 patients. Clin Orthop Relat Res 2012;470:2605–12.

[34] Fu Y, Shi Z, Han B, et al. Comparing efficacy and safety of 2 methods of tranexamic acid administration in reducing blood loss following total knee arthroplasty; a meta-analysis. Medicine 2016;95:e5583.

[35] Lotke PA, Faralli VJ, Orenstein EM, et al. Blood loss after total knee replacement. Effects of tourniquet release and continuous passive motion. J Bone Joint Surg Am 1991;73:1037–40.

[36] Fukui D, Kawakami M, Nakao SI, et al. Reduced blood loss and operation time in lumbar posterolateral fusion using a bipolar sealer. Eur Spine J 2017;26:726–32.

[37] Ng YY, Arnott L, McShane M. Periprosthetic femoral condyle fracture after total knee arthroplasty and saline-coupled bipolar sealing technology. Orthopedics 2011;34:53.

[38] Huang Z, Ma J, Shen B, et al. Use of a bipolar blood-sealing system during total joint arthroplasty. Orthopedics 2015;38:757–63.